Literature DB >> 28119318

Reply to "Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin".

Juan Aguilar-Company1, Ibai Los-Arcos2, Carlos Pigrau1,3, Benito Almirante2,3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28119318      PMCID: PMC5278696          DOI: 10.1128/AAC.02448-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  3 in total

1.  Potential Use of Fosfomycin-Tromethamine for Treatment of Recurrent Campylobacter Species Enteritis.

Authors:  Juan Aguilar-Company; Ibai Los-Arcos; Carles Pigrau; Dolors Rodríguez-Pardo; María Nieves Larrosa; Virginia Rodríguez-Garrido; Denisse Sihuay-Diburga; Benito Almirante
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

2.  Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin.

Authors:  Antonio Sorlózano-Puerto; José María Navarro-Marí; José Gutiérrez-Fernández
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

3.  Susceptibilities of fluoroquinolone-resistant strains of Campylobacter jejuni to 11 oral antimicrobial agents.

Authors:  J L Gomez-Garces; R Cogollos; J L Alos
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.